Relevant outcomes in intervention trials for sarcopenia

Journal of the American Geriatrics Society

Volumn 59, Issue 8, 2011, Pages 1566-1567

  Vandewoude, Maurits F J ^a   Cederholm, Tommy ^b   Cruz Jentoft, Alfonso J ^c  

^a UNIVERSITY OF ANTWERP   (Belgium)

^b UPPSALA UNIVERSITY   (Sweden)

^c HOSPITAL RAMÓN Y CAJAL   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

FALLING; FRACTURE; GAIT; GRIP STRENGTH; HUMAN; LETTER; MUSCLE ATROPHY; MUSCLE FUNCTION; MUSCLE MASS; MUSCLE STRENGTH; OUTCOME ASSESSMENT; PHYSICAL PERFORMANCE; TREATMENT OUTCOME;

HUMANS; SARCOPENIA;

EID: 80051754392     PISSN: 00028614     EISSN: 15325415     Source Type: Journal    
DOI: 10.1111/j.1532-5415.2011.03512.x     Document Type: Letter

References (4)

1. Brass E, Sietsema K., Considerations in the development of drugs to treat sarcopenia. J Am Geriatr Soc 2011; 59: 530-535.
2. Cruz-Jentoft A, Baeyens JP, Bauer J, et al,. Sarcopenia: European consensus on definition and diagnosis. Age Ageing 2010; 39: 412-423.
3. Cruz-Jentoft AJ, Landi F, Topinková E, et al,. Understanding sarcopenia as a geriatric syndrome. Curr Opin Clin Nutr Metab Care 2010; 13: 1-7.
4. Bauer JM, Sieber CC., Sarcopenia and frailty: A clinician's controversial point of view. Exp Gerontol 2008; 43: 674-678.